Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment.
- 1Department of Ophthalmology, Rostock University Medical Center, Doberaner Straße. 140, 18057, Hanseatic and University City of Rostock, Germany. [email protected].
- 2Department of Ophthalmology, Rostock University Medical Center, Doberaner Straße. 140, 18057, Hanseatic and University City of Rostock, Germany.
Abstract
Background
Proliferative vitreoretinopathy (PVR) remains the major cause of surgical failure in rhegmatogenous retinal detachment (RRD). This study evaluates the anatomical and functional outcomes, as well as the safety, of a standardized intraoperative intravitreal methotrexate infusion protocol during pars plana vitrectomy (PPV) in eyes with early stage PVR (grade B) or with advanced PVR (grade C).Methods
A retrospective case series was conducted on 60 consecutive eyes of 59 patients with RRD and PVR grade B (n = 29) or grade C (n = 31) undergoing PPV with adjunct intraoperative methotrexate between November 2024 and February 2026 at a German tertiary center. Methotrexate 40 mg was administered via a 500 mL balanced salt solution infusion. Functional and structural testing included best-corrected visual acuity (BCVA), intraocular pressure, multifocal electroretinogram, perimetry, and spectral-domain optical coherence tomography. The primary outcome measure was single-surgery anatomical success (SSAS) at 12 weeks after primary surgery or after silicone oil removal. Secondary outcomes included BCVA changes and complication rates.Results
SSAS was achieved in 81.7% of all eyes, with a significantly higher success rate in eyes with PVR grade B compared to PVR grade C (93.1% versus 71.0%; p = 0.043). At 12 weeks, BCVA improved significantly in macula-off cases (p < 0.001) and remained stable in macula-on cases. In an exploratory subset of 17 patients postoperative multifocal electroretinogram and perimetry demonstrated preserved central retinal function. No ocular or systemic adverse events related to methotrexate occurred.Conclusions
The standardized intraoperative intravitreal methotrexate infusion protocol was safe, feasible, and associated with high single-surgery reattachment rates, particularly in PVR grade B eyes. Anatomical outcomes in PVR grade C eyes were comparable to other complex PVR cohorts, without any drug-related local or systemic toxicity.Trial registration
Not applicable (retrospective observational study).
Related
- SEMA3A in Proliferative Vitreoretinopathy: Exogenous Activity, Endogenous Regulation, and the MicroRNA Hypothesis
- Successful management of high-risk proliferative diabetic retinopathy during pregnancy with intravitreal faricimab
- Comparison of Intravitreal Antivascular Endothelial Growth Factor Therapy in Treatment-Naïve vs Panretinal Photocoagulation–Treated Eyes With Proliferative Diabetic Retinopathy
- Suprachoroidal hemorrhage and detachment in the non-laser photocoagulation posterior pole after intravitreal Anti-VEGF injection: A case report
- Application of ultra-widefield scanning laser ophthalmoscopy in early familial exudative vitreoretinopathy
BibTeX
@article{luyken2026intravitreal,
title = {{Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment.}},
author = {Adrian Konstantin Luyken and Claudia Brockmann and Valentin Junge and André Schulz and Thomas Armin Fuchsluger and Friederike Schaub},
journal = {BMC ophthalmology},
year = {2026},
month = oct,
doi = {10.1186/s12886-026-05455-8},
url = {https://europepmc.org/article/MED/42897487},
note = {CC BY},
}
RIS
TY - JOUR
TI - Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment.
AU - Adrian Konstantin Luyken
AU - Claudia Brockmann
AU - Valentin Junge
AU - André Schulz
AU - Thomas Armin Fuchsluger
AU - Friederike Schaub
PY - 2026
DA - 2026/10/17
JO - BMC ophthalmology
DO - 10.1186/s12886-026-05455-8
UR - https://europepmc.org/article/MED/42897487
AB - Background Proliferative vitreoretinopathy (PVR) remains the major cause of surgical failure in rhegmatogenous retinal detachment (RRD). This study evaluates the anatomical and functional outcomes, as well as the safety, of a standardized intraoperative intravitreal methotrexate infusion protocol during pars plana vitrectomy (PPV) in eyes with early stage PVR (grade B) or with advanced PVR (grade C).Methods A retrospective case series was conducted on 60 consecutive eyes of 59 patients with RRD and PVR grade B (n = 29) or grade C (n = 31) undergoing PPV with adjunct intraoperative methotrexate between November 2024 and February 2026 at a German tertiary center. Methotrexate 40 mg was administered via a 500 mL balanced salt solution infusion. Functional and structural testing included best-corrected visual acuity (BCVA), intraocular pressure, multifocal electroretinogram, perimetry, and spectral-domain optical coherence tomography. The primary outcome measure was single-surgery anatomical success (SSAS) at 12 weeks after primary surgery or after silicone oil removal. Secondary outcomes included BCVA changes and complication rates.Results SSAS was achieved in 81.7% of all eyes, with a significantly higher success rate in eyes with PVR grade B compared to PVR grade C (93.1% versus 71.0%; p = 0.043). At 12 weeks, BCVA improved significantly in macula-off cases (p < 0.001) and remained stable in macula-on cases. In an exploratory subset of 17 patients postoperative multifocal electroretinogram and perimetry demonstrated preserved central retinal function. No ocular or systemic adverse events related to methotrexate occurred.Conclusions The standardized intraoperative intravitreal methotrexate infusion protocol was safe, feasible, and associated with high single-surgery reattachment rates, particularly in PVR grade B eyes. Anatomical outcomes in PVR grade C eyes were comparable to other complex PVR cohorts, without any drug-related local or systemic toxicity.Trial registration Not applicable (retrospective observational study).
SN - 1471-2415
ER -